Hans Peter Hasler has been named chief operating officer, Biogen Idec. Mr. Hasler has served as executive vice president, global neurology and head of International. In his new role, he will oversee all commercial operations as well as the company’s business development function.
   
“In view of the continued expansion of our commercial businesses, and the advances of our extensive pipeline, it is important to further integrate Biogen Idec’s commercial units,” said James C. Mullen, Biogen Idec’s chief executive officer. “Bringing together these businesses to enhance our commercial and new product opportunities on a global basis is a logical step in the continued implementation of our growth strategy -- and Hans Peter Hasler is the ideal person to fill this new organizational role. Over the last few years, Hans Peter has led the great success and growth of our business outside the U.S. I am confident that we will continue meeting and exceeding our goals under his strong and capable leadership.”
   
Mr. Hasler joined the company in 2001 from Wyeth Pharmaceuticals where he worked for eight years, serving since 1998 as senior vice president, head of Global Strategic Marketing. He was also a member of the Wyeth executive committee and chair of the Commercial Council. From 1993 to 1998, he served in senior management capacities, including managing director of Wyeth Group, Germany; general manager of Wyeth in Switzerland; and general manager of central Eastern Europe. Prior to joining Wyeth, Mr. Hasler held several positions at Abbott and Sanofi Pharma in Switzerland.

News from our sister sites